Fig. 2.

Tsg101-transgenic (TG) hearts exhibit improved recovery of cardiac function after I/R injury. (A) Schematic diagram showing the Tsg101-TG construct. (B) Representative Western blots and (C) quantification analyses showing the Tsg101 expression in heart, liver, spleen, lung, and kidney of WT- and TG-mice (FVB/N, male, 10-12-week old). (D/E) Tsg101-overexpressing hearts (TG) showed better contractile function recovery after 45-min global ischemia followed by 1-h reperfusion, compared to wild-type (WT) hearts. n = 6 for WT, n = 6 for TG. *, p < 0.05 vs. WT. (F) Total LDH in the coronary effluent collected during the first 10 min of reperfusion from WT- and TG-hearts. *, p < 0.05 vs. WT. Representative images (G) and quantitative results (H) of the TUNEL staining in WT- and TG-hearts after ex vivo I/R (45min/2 h). Green, TUNEL-positive nuclei; Red, α-actinin; blue, DAPI. *, p < 0.05 vs. WT. (I) Caspase-3 activity in the WT- and TG-hearts subjected to ex vivo I/R (45min/1 h). *, p < 0.05 vs. WT. (J) Representative in vivo myocardial infarction images (white/gray: infarct size; red: area at risk; and blue: non-ischemic area) and (K) quantitative results of infarction size and (L) the ratio of risk region to left ventricular (LV) area. *, p < 0.05 vs. WTs. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)